Standard BioTools Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Standard BioTools Inc. (LAB) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- Standard BioTools Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $1.25M, a 12.75% decline year-over-year.
- Standard BioTools Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.35M, a 5.77% decline year-over-year.
- Standard BioTools Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.57M, a 12.22% increase year-over-year.
- Standard BioTools Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $1.43M, a 5.06% decline year-over-year.
- Standard BioTools Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $497.00K, a 75.36% decline from fiscal 2020.
- Standard BioTools Inc. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $2.02M.
- Standard BioTools Inc. operating lease, right-of-use asset, amortization expense for fiscal 2019 was -$516.00K.
- Standard BioTools Inc. operating lease, right-of-use asset, amortization expense for fiscal 2018 was $0.00.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.60M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $1.35M 10-Q · filed 2026-05-06 | |||
| 2025-09-30 | $1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.00M derived: sum of 2 quarters · filed 2026-08-05 | $4.43M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.87M 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $1.44M 10-Q · filed 2026-05-06 | |||
| 2024-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.90M derived: sum of 2 quarters · filed 2025-11-04 | $4.35M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $2.95M 10-Q · filed 2025-08-15 | ||
| 2024-03-31 | $1.45M 10-Q · filed 2025-05-06 | |||
| 2021-12-31 | $117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $232.00K derived: sum of 2 quarters · filed 2022-03-08 | $346.00K derived: sum of 3 quarters · filed 2022-03-08 | $497.00K 10-K · filed 2022-03-08 |
| 2021-09-30 | $115.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $229.00K derived: sum of 2 quarters · filed 2021-11-09 | $380.00K 10-Q · filed 2021-11-09 | $534.00K derived: sum of 4 quarters · filed 2022-03-08 |
| 2021-06-30 | $114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $265.00K 10-Q · filed 2021-08-06 | $419.00K derived: sum of 3 quarters · filed 2022-03-08 | $951.00K derived: sum of 4 quarters · filed 2022-03-08 |
| 2021-03-31 | $151.00K 10-Q · filed 2021-05-07 | $305.00K derived: sum of 2 quarters · filed 2022-03-08 | $837.00K derived: sum of 3 quarters · filed 2022-03-08 | $1.79M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-12-31 | $154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $686.00K derived: sum of 2 quarters · filed 2022-03-08 | $1.64M derived: sum of 3 quarters · filed 2022-03-08 | $2.02M 10-K · filed 2022-03-08 |
| 2020-09-30 | $532.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.48M derived: sum of 2 quarters · filed 2021-11-09 | $1.86M 10-Q · filed 2021-11-09 | $1.72M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | $951.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $1.33M 10-Q · filed 2021-08-06 | $1.19M derived: sum of 3 quarters · filed 2022-03-08 | $1.06M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $380.00K 10-Q · filed 2021-05-07 | $235.00K derived: sum of 2 quarters · filed 2022-03-08 | $114.00K derived: sum of 3 quarters · filed 2022-03-08 | |
| 2019-12-31 | -$145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$266.00K derived: sum of 2 quarters · filed 2022-03-08 | -$516.00K 10-K · filed 2022-03-08 | |
| 2019-09-30 | -$121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$371.00K 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | -$250.00K 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |